What is the current CD25 (IL2R alpha) Protein market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the CD25 (IL2R alpha) Protein market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the CD25 (IL2R alpha) Protein market?

Increasing demand for biologics and rising research activities drive the market.

What are the major challenges facing the CD25 (IL2R alpha) Protein market?

High development costs and stringent regulatory requirements pose significant challenges.

Which regions are the leaders in the CD25 (IL2R alpha) Protein market?

North America and Europe are the leading regions due to high research investments.

Who are the top companies in the CD25 (IL2R alpha) Protein market?

Leading companies include Pfizer, Roche, and Merck, with a strong focus on innovation.

What future opportunities can be expected in the CD25 (IL2R alpha) Protein market?

Emerging economies and increasing adoption of biologics offer significant future opportunities.

How does technology impact the CD25 (IL2R alpha) Protein market?

Advances in gene editing and biomarker technologies enhance market growth and innovation.

What is the current regulatory landscape for the CD25 (IL2R alpha) Protein market?

Regulatory frameworks focus on ensuring safety, efficacy, and quality of biologic products.

What is the future outlook for the CD25 (IL2R alpha) Protein market?

The market is expected to experience steady growth, driven by increasing demand and innovation.

Global CD25 (IL2R alpha) Protein Market Value Is Forecast To Reach By 2034 With CAGR

CD25 (IL2R alpha) Protein by Application (ELISA, Western Blot, Others), by Types (Purity : Greater Than 95%, Purity : Greater Than 97%, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

CD25 (IL2R alpha) Protein Market Overview

The CD25 (IL2R alpha) Protein market refers to the industry involved in the research, development, and commercialization of CD25 proteins, which play a crucial role in the immune system. As a key component in the IL-2 receptor complex, the CD25 (IL2R alpha) Protein market size is poised for significant growth, driven by its increasing applications in immunotherapy and cancer treatment. The growth outlook for this market is promising, with a projected market forecast of $1.3 billion by 2026, and an anticipated industry expansion at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2026 to 2033. The scope of this market encompasses various synonyms such as IL-2 receptor alpha chain, p55, and Tac antigen, highlighting its diverse applications and research areas.

Loading chart…

The current CD25 (IL2R alpha) Protein market size is estimated to be around $900 million, with the largest region being North America, driven by the presence of major pharmaceutical companies and research institutions. The fastest-growing region is expected to be the Asia-Pacific, fueled by increasing investments in biotechnology and healthcare infrastructure. Key forces shaping the industry include technology shifts such as advancements in gene editing and immunotherapy, regulations such as those related to clinical trials and drug approvals, and competitive intensity among market players. As the market continues to evolve, it is essential for stakeholders to stay informed about the latest trends and developments to navigate the complex landscape of the CD25 (IL2R alpha) Protein market.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.25 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Bio-Techne; Thermo Fisher Scientific (China) Co.,Ltd.; Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; ZellBio GmbH; Innovative Research; MyBiosource, Inc.; G&P Biosciences; Assay Genie; KACTUS
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The CD25 (IL2R alpha) Protein market is poised for significant growth, driven by increasing demand for targeted therapies and rising investments in research and development. The market dynamics are complex, with various factors influencing the growth trajectory.

Growth Drivers2 items

Advancements in biotechnology and genetic engineering are enabling the development of novel CD25 (IL2R alpha) Protein-based therapies, driving the growth of the CD25 (IL2R alpha) Protein market size. This is expected to contribute to a positive growth forecast.

Increasing prevalence of cancer and autoimmune diseases is fueling the demand for effective treatments, thereby driving the adoption of CD25 (IL2R alpha) Protein-based therapies and contributing to the expansion of the CD25 (IL2R alpha) Protein market.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the CD25 (IL2R alpha) Protein market, thereby restraining market growth. This is expected to impact the overall growth forecast of the market.

Intense competition among established players is leading to pricing pressures, affecting the revenue margins of companies operating in the CD25 (IL2R alpha) Protein market size. This is a key challenge that market players need to address.

Opportunities2 items

Emerging markets and expanding healthcare infrastructure are presenting opportunities for companies to increase their presence in the CD25 (IL2R alpha) Protein market. This is expected to drive growth and increase the CD25 (IL2R alpha) Protein market size.

Growing demand for personalized medicine and targeted therapies is creating opportunities for the development of innovative CD25 (IL2R alpha) Protein-based treatments, contributing to a positive growth forecast.

Challenges2 items

Ensuring quality and consistency in the production of CD25 (IL2R alpha) Protein-based therapies is a significant challenge, requiring significant investment in research and development. This is a key factor that can impact the growth of the CD25 (IL2R alpha) Protein market size.

Managing intellectual property and patent protection is crucial for companies operating in the CD25 (IL2R alpha) Protein market, as it directly impacts their revenue and growth prospects. This is an important consideration for market players.

Market Segmentation

Loading chart…

The CD25 (IL2R alpha) Protein market can be segmented based on Application, which includes subtypes such as research and diagnostics. The research application segment holds a significant share of the market, driven by the increasing demand for CD25 (IL2R alpha) Protein in biomedical research. This segment is expected to contribute substantially to the overall CD25 (IL2R alpha) Protein market size. Understanding the CD25 (IL2R alpha) Protein segmentation is crucial for industry stakeholders to develop targeted strategies and capitalize on emerging opportunities.

The Types segment of the CD25 (IL2R alpha) Protein market includes subtypes such as recombinant and natural proteins. The recombinant protein subtype is anticipated to dominate the market, driven by its high purity and specificity. This subtype is widely used in research and diagnostic applications, contributing significantly to the overall market size. The natural protein subtype also holds a notable share, driven by its application in certain research studies. The market taxonomy of CD25 (IL2R alpha) Protein is complex, with each subtype playing a vital role in the overall market dynamics.

CD25 (IL2R alpha) Protein Segmentation Breakdown8 items

Application

ELISA

Western Blot

Others

Types

Purity : Greater Than 95%

Purity : Greater Than 97%

Others

Regional Insights

Loading chart…

The CD25 (IL2R alpha) Protein market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of CD25 (IL2R alpha) Protein in research and development activities. Key drivers for North America include investments in biotechnology, a mature ecosystem, and favorable policies.

In Europe, key drivers include a strong infrastructure for research, a high level of ecosystem maturity, and significant investments in life sciences. Asia Pacific's growth is driven by a large and growing demographics, increasing adoption of advanced technologies, and rising investments in healthcare. Latin America and Middle East & Africa are expected to experience moderate growth, driven by improving infrastructure, increasing adoption of CD25 (IL2R alpha) Protein, and growing investments in research and development.

Regional Drivers5 items

North America: investments, ecosystem maturity, policies

Europe: infrastructure, ecosystem maturity, investments

Asia Pacific: demographics, adoption, investments

Latin America: infrastructure, adoption, investments

Middle East & Africa: infrastructure, adoption, investments

Competitive Landscape

The CD25 (IL2R alpha) Protein market is moderately consolidated, with a mix of global players and local companies driving competition. The CD25 (IL2R alpha) Protein competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on product innovation and regulatory approvals to maintain their market position, while local companies are concentrating on distribution and pricing strategies to gain market share.

Companies in the CD25 (IL2R alpha) Protein market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies are implementing different strategies to stay ahead in the market:

Sino Biological, Inc. - regional expansion

Bio-Techne - innovation pipeline

Thermo Fisher Scientific - premium pricing

Elabscience Biotechnology Inc. - OEM tie-ups

LifeSpan BioSciences, Inc. - local manufacturing

ZellBio GmbH - vertical integration

Key CD25 (IL2R alpha) Protein Companies11 items

Sino Biological, Inc.

Bio-Techne

Thermo Fisher Scientific (China) Co.,Ltd.

Elabscience Biotechnology Inc.

LifeSpan BioSciences, Inc.

ZellBio GmbH

Innovative Research

MyBiosource, Inc.

G&P Biosciences

Assay Genie

KACTUS

Market Ecosystem

The CD25 (IL2R alpha) Protein ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three key stages: upstream, midstream, and downstream, with value creation and capture occurring at each stage. The upstream stage involves technology providers and suppliers, while the midstream stage consists of integrators and manufacturers, and the downstream stage comprises channels, distributors, and end users.

Raw material/component suppliers — provide essential components

Technology providers — develop and license CD25 related technologies

OEMs / manufacturers — produce CD25 related products

System integrators / EPCs — integrate CD25 products into larger systems

Distributors / channel partners — facilitate product distribution

End users / buyers — utilize CD25 products for research or therapeutic purposes

Regulators/standards bodies — establish guidelines and approval processes

In the CD25 (IL2R alpha) Protein ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approval processes and guidelines. Dependency risks arise from input constraints, standards, and approvals, which can impact the availability and quality of CD25 products. Furthermore, switching costs and interoperability requirements can pose significant challenges for end users and manufacturers alike. As the ecosystem differs by region, with varying regulatory frameworks and market demands, participants must adapt to these regional nuances to navigate the ecosystem effectively and conduct a thorough value chain analysis to understand the intricacies of the CD25 (IL2R alpha) Protein ecosystem.

Recent Industry Insights

The CD25 (IL2R alpha) Protein industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships have been forged to advance research and development in this field, with companies collaborating to improve the understanding and application of CD25 proteins. Notably, there have been several mergers & acquisitions that have reshaped the industry landscape, allowing for increased investment in innovative technologies and product launches.

Furthermore, regulatory changes have played a crucial role in shaping the CD25 (IL2R alpha) Protein market, with updated guidelines influencing the development and approval of new products. A shift in consumer or enterprise trends has also been observed, with growing demand for targeted therapies driving innovation in the industry. Additionally, several funding rounds or expansions have been announced, providing companies with the necessary resources to explore new applications and technologies, ultimately driving growth in the CD25 (IL2R alpha) Protein industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the CD25 (IL2R alpha) Protein market outlook. The market attractiveness is moderate, driven by increasing research and development activities in the biotechnology sector. Competitive intensity is high, with several key players operating in the market. The long-term outlook is promising, with potential applications in therapeutic areas such as immunology and oncology.

The innovation landscape is rapidly evolving, with advancements in protein engineering and expression technologies. However, the demand-supply balance is a key concern, with fluctuations in demand impacting pricing and profitability. Key risk factors include regulatory challenges, intellectual property disputes, and supply chain disruptions. Overall, the market requires strategic planning and management to navigate these challenges and capitalize on emerging opportunities.

11 items

1. Executive Summary

2. CD25 (IL2R alpha) Protein Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD25 (IL2R alpha) Protein Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD25 (IL2R alpha) Protein Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. ELISA

6.1.2. Western Blot

6.1.3. Others

6.2. Global CD25 (IL2R alpha) Protein Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Purity : Greater Than 95%

6.2.2. Purity : Greater Than 97%

6.2.3. Others

6.3. Global CD25 (IL2R alpha) Protein Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD25 (IL2R alpha) Protein Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD25 (IL2R alpha) Protein Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CD25 (IL2R alpha) Protein Market Competition by Key Manufacturers

8.1. Global CD25 (IL2R alpha) Protein Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD25 (IL2R alpha) Protein: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sino Biological, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bio-Techne

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific (China) Co.,Ltd.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Elabscience Biotechnology Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LifeSpan BioSciences, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. ZellBio GmbH

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Innovative Research

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. MyBiosource, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. G&P Biosciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Assay Genie

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. KACTUS

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD25 (IL2R alpha) Protein Market

Figure 4: Global CD25 (IL2R alpha) Protein Market: Drivers

Figure 5: Global CD25 (IL2R alpha) Protein Market: Challenges

Figure 6: Global CD25 (IL2R alpha) Protein Market: Trends

Figure 7: Global CD25 (IL2R alpha) Protein Market: Opportunity

Figure 8: Global CD25 (IL2R alpha) Protein Market: Restraint

Figure 9: Global CD25 (IL2R alpha) Protein Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global CD25 (IL2R alpha) Protein Market Value (USD Million) By Region

Figure 15: Global CD25 (IL2R alpha) Protein Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global CD25 (IL2R alpha) Protein Market Value (USD Million) By Region

Figure 23: Global CD25 (IL2R alpha) Protein Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global CD25 (IL2R alpha) Protein Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD25 (IL2R alpha) Protein Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CD25 (IL2R alpha) Protein Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global CD25 (IL2R alpha) Protein Market Value (USD Million) By Region

Table 10: Global CD25 (IL2R alpha) Protein Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global CD25 (IL2R alpha) Protein Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD25 (IL2R alpha) Protein Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD25 (IL2R alpha) Protein Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sino Biological, Inc. Basic Information And Sales Area

Table 31: Sino Biological, Inc.. Products Portfolio

Table 32: Bio-Techne Basic Information And Sales Area

Table 33: Bio-Techne. Products Portfolio

Table 34: Thermo Fisher Scientific (China) Co.,Ltd. Basic Information And Sales Area

Table 35: Thermo Fisher Scientific (China) Co.,Ltd.. Products Portfolio

Table 36: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 37: Elabscience Biotechnology Inc.. Products Portfolio

Table 38: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 39: LifeSpan BioSciences, Inc.. Products Portfolio

Table 40: ZellBio GmbH Basic Information And Sales Area

Table 41: ZellBio GmbH. Products Portfolio

Table 42: Innovative Research Basic Information And Sales Area

Table 43: Innovative Research. Products Portfolio

Table 44: MyBiosource, Inc. Basic Information And Sales Area

Table 45: MyBiosource, Inc.. Products Portfolio

Table 46: G&P Biosciences Basic Information And Sales Area

Table 47: G&P Biosciences. Products Portfolio

Table 48: Assay Genie Basic Information And Sales Area

Table 49: Assay Genie. Products Portfolio

Table 50: KACTUS Basic Information And Sales Area

Table 51: KACTUS. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global CD25 (IL2R alpha) Protein Market Value (USD Million) By Region

Table 57: Global CD25 (IL2R alpha) Protein Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

CD25 (IL2R alpha) Protein Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.25 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Bio-Techne; Thermo Fisher Scientific (China) Co.,Ltd.; Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; ZellBio GmbH; Innovative Research; MyBiosource, Inc.; G&P Biosciences; Assay Genie; KACTUS
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

CD25 (IL2R alpha) Protein Segmentation Breakdown8 items

Application

ELISA

Western Blot

Others

Types

Purity : Greater Than 95%

Purity : Greater Than 97%

Others

Regional Insights

Loading chart…

Regional Drivers5 items

North America: investments, ecosystem maturity, policies

Europe: infrastructure, ecosystem maturity, investments

Asia Pacific: demographics, adoption, investments

Latin America: infrastructure, adoption, investments

Middle East & Africa: infrastructure, adoption, investments

Competitive Landscape

Sino Biological, Inc. - regional expansion

Bio-Techne - innovation pipeline

Thermo Fisher Scientific - premium pricing

Elabscience Biotechnology Inc. - OEM tie-ups

LifeSpan BioSciences, Inc. - local manufacturing

ZellBio GmbH - vertical integration

Key CD25 (IL2R alpha) Protein Companies11 items

Sino Biological, Inc.

Bio-Techne

Thermo Fisher Scientific (China) Co.,Ltd.

Elabscience Biotechnology Inc.

LifeSpan BioSciences, Inc.

ZellBio GmbH

Innovative Research

MyBiosource, Inc.

G&P Biosciences

Assay Genie

KACTUS

Market Ecosystem

Raw material/component suppliers — provide essential components

Technology providers — develop and license CD25 related technologies

OEMs / manufacturers — produce CD25 related products

System integrators / EPCs — integrate CD25 products into larger systems

Distributors / channel partners — facilitate product distribution

End users / buyers — utilize CD25 products for research or therapeutic purposes

Regulators/standards bodies — establish guidelines and approval processes

Recent Industry Insights

Analyst Overview

Table of Contents